STOCK TITAN

Eikon Therapeutics (EIKN) Stock News

EIKN NASDAQ

Eikon Therapeutics reports company news centered on clinical-stage oncology development, financial results, public-company milestones, and capital-structure updates. Recurring developments include progress across EIK1001, EIK1003, and EIK1004, including lung cancer, prostate cancer, breast cancer, ovarian cancer, and advanced solid tumor programs.

The company’s news also covers corporate updates following its Nasdaq listing, shareholder voting matters, clinical or regulatory disclosures, and financial reporting for a late-stage biopharmaceutical issuer that operates through a single drug discovery and clinical development segment.

Rhea-AI Summary

Eikon Therapeutics (Nasdaq: EIKN) reported a third-quarter 2026 net loss attributable to common stockholders of $86.1 million alongside oncology trial updates. The loss widened from $71.1 million a year earlier, while loss per share narrowed to $1.59 from $24.24. Research and development expenses rose 21% to $71.8 million; general and administrative expenses increased 21% to $18.7 million.

Cash, cash equivalents and marketable securities totaled $461.7 million at September 30. Eikon expects funding to last into the first quarter of 2028. In the ongoing Phase 2 TeLuRide-005 lung cancer trial, EIK1001 with pembrolizumab and chemotherapy produced a 63.1% objective response rate among 65 efficacy-evaluable participants. Eikon also dosed the first patient in registrational trial TeLuRide-008, reported early-stage results for other oncology candidates and submitted an application to begin clinical testing of EIK1006.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.45%
Tags
-
Rhea-AI Summary

Eikon Therapeutics (EIKN) announced that its chief executive and chief medical officer will participate in three November investor events. CEO Roger M. Perlmutter will join the JP Morgan Biotech Call Series on November 6 and Guggenheim’s healthcare conference on November 10, 2026. CMO Roy Baynes will join Morgan Stanley’s November 3, 2026 webcast on new data and the evolving synthetic lethality landscape.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.97%
Tags
none
-
Rhea-AI Summary

Eikon Therapeutics (EIKN) presented updated TeLuRide-005 results evaluating EIK1001 with pembrolizumab and chemotherapy in previously untreated stage 4 lung cancer. The open-label trial enrolled 72 participants with non-small cell lung cancer. Among 65 efficacy-evaluable participants, the objective response rate, measuring tumor shrinkage, was 63.1%; disease control was 89.2% after median follow-up of 17.2 months.

The squamous cohort had a 72% response rate, 100% disease control and median response duration of 12.9 months. The non-squamous cohort had 55.6% response and 80.6% disease control. Among 72 safety-evaluable participants, Grade 3 or higher treatment-related adverse events occurred in 48.6%, and treatment-related events caused discontinuation in 6.9%; none caused death. TeLuRide-008, a Phase 2/3 trial, is enrolling; Eikon expects its dose-selection interim analysis in second-half 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.69%
Tags
none
Rhea-AI Summary

Eikon Therapeutics (EIKN) presented early clinical results for three cancer drug programs at the European Society for Medical Oncology Congress. In ongoing Phase 1/2 studies, EIK1003 produced objective response rates, measuring tumor shrinkage, of 14.3% alone, 20.8% with abiraterone and 26.4% with paclitaxel among efficacy-evaluable participants. Grade 3 or higher treatment-emergent adverse events occurred in 43.1%, 45.0% and 80.3% of participants in those respective cohorts.

EIK1004 monotherapy produced a 12.1% response rate; Grade 3 or higher adverse events occurred in 17.6% of treated participants. Preliminary EIK1005 results showed stable disease in 6 of 8 evaluable monotherapy participants and a partial response in the single pembrolizumab-combination participant. Eikon expects further results across the programs in 2027, including EIK1003 and EIK1004 combination data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.89%
Tags
none
-
Rhea-AI Summary

Eikon Therapeutics (Nasdaq: EIKN) announced the availability of seven abstracts covering four clinical candidates for presentation at the 2026 ESMO Congress.

The congress begins October 23, 2026, in Madrid, Spain. Presentations cover EIK1001 studies in stage 4 non-small cell lung cancer, EIK1003 studies in advanced solid tumors and metastatic prostate cancer, and an EIK1004 study in advanced solid tumors. EIK1005 presentations include a study overview and preliminary safety, tolerability and pharmacokinetic data, which describe how the drug moves through the body. Listed presentations are scheduled for October 23 and October 26.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
none
-
Rhea-AI Summary

Eikon Therapeutics (EIKN) submitted an Investigational New Drug application to the FDA to evaluate EIK1006 for advanced metastatic prostate cancer.

An Investigational New Drug application is a submission for clinical testing of an experimental medicine. EIK1006 is an internally derived androgen receptor antagonist, a drug designed to block that receptor, structurally unrelated to currently available lutamide-class antagonists. The candidate targets the wild-type receptor and clinically relevant variants implicated in resistance to conventional prostate cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.56%
Tags
none
Rhea-AI Summary

Eikon Therapeutics (EIKN) has appointed Ching-Pin (CP) Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer. He joins from Bristol Myers Squibb, where he was Vice President, Head of Cardiovascular Discovery Biology and Translational Pharmacology.

Dr. Chang previously led cardiovascular research at Gilead Sciences and served as Vice President of Disease Biology at MyoKardia, where he built a disease biology program focused on genetic causes of cardiomyopathies and the characterization of mavacamten for hypertrophic cardiomyopathy. He also held academic leadership roles at Stanford University and Indiana University School of Medicine, focusing on developmental genetics and heart failure. His training includes an M.D. from National Taiwan University, a Ph.D. in cancer biology from Stanford, and clinical and research fellowships at Massachusetts General Hospital, Stanford, and the Howard Hughes Medical Institute.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
none
-
Rhea-AI Summary

Eikon Therapeutics (Nasdaq:EIKN) announced that Chairman and CEO Roger M. Perlmutter and CFO Freddie Bowie will participate in two investor conferences in New York in September 2026: the 12th Annual Cantor Global Healthcare Conference on September 10 at 2:10 pm ET and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15 at 4:05 pm ET, both in fireside chat format. Live and archived webcasts (for about 30 days) will be available via Eikon’s investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.54%
Tags
conferences
-
Rhea-AI Summary

Eikon Therapeutics (Nasdaq:EIKN) announced that Chairman and CEO Roger M. Perlmutter will participate in a Cantor Fitzgerald-hosted key opinion leader event on August 20, 2026 at 9:00 AM ET.

The session will feature MD Anderson oncologist Dr. Timothy A. Yap, an expert on PARP inhibitors, discussing their therapeutic use across several cancers. An archived webcast replay will be available on Eikon’s investor website for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
none
Rhea-AI Summary

Eikon Therapeutics (Nasdaq: EIKN) reported second quarter 2026 results, highlighting major clinical and corporate progress. Seven abstracts featuring all four current clinical candidates (EIK1001, EIK1003, EIK1004, EIK1005) were accepted for presentation at the ESMO Congress 2026, building on data presented at ASCO 2026.

For EIK1001, an independent Data Monitoring Committee completed the first interim analysis of the TeLuRide-006 Phase 2/3 melanoma trial, selected a single dosing regimen, and recommended continuation. Eikon also dosed the first patient in TeLuRide-008, a Phase 2/3 NSCLC trial. Updated and initial data for EIK1003, EIK1004 and EIK1005 will be presented at ESMO.

Financially, Eikon ended June 30, 2026 with $531.2 million in cash, cash equivalents and marketable securities, which it expects will fund operations into the second half of 2027. Q2 2026 R&D expenses were $75.5 million (up 9% year over year), G&A expenses were $17.9 million (down 56%), and net loss attributable to common stockholders was $88.4 million versus $105.2 million a year earlier.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.97%
Tags

FAQ

What is the current stock price of Eikon Therapeutics (EIKN)?

Eikon Therapeutics (EIKN) last closed at $5.98.

What is the market cap of Eikon Therapeutics (EIKN)?

The market cap of Eikon Therapeutics (EIKN) is approximately $324.0M.